Durability of Implanted Vagus Nerve Stimulation in US TRD Care

Durable Antidepressant Effects of VNS in Treatment-Resistant Depression

Implanted vagus nerve stimulation (VNS) provides sustained antidepressant benefits for individuals with severe, treatment-resistant depression (TRD), as evidenced by recent large-scale clinical trial data. The multicenter RECOVER trial, the largest of its kind, reported that approximately 80% of participants maintained durable improvements in depressive symptoms, clinical impression, quality of life, and daily function at two years, with about 70% sustaining benefits at three years. These results are particularly notable given the study population: patients with a mean of 27 years of depressive illness and an average of 13 failed antidepressant trials. VNS, approved by the US Food and Drug Administration (FDA) for TRD in 2005, involves surgical implantation of a pulse generator connected to the cervical vagus nerve, delivering intermittent electrical stimulation around the clock.

Mechanisms Underpinning VNS Efficacy and Durability

Multiple converging lines of evidence suggest that VNS exerts its antidepressant effects through several synergistic biological mechanisms. Preclinical and clinical research indicates that VNS modulates neurotransmitter systems, including monoamines such as serotonin and norepinephrine, which are central to mood regulation. In addition, VNS appears to reduce neuroinflammation, enhance neuroplasticity within key brain circuits implicated in depression, and modulate large-scale brain networks involved in emotional processing. The unique anatomical entry point of the vagus nerve—via the nucleus tractus solitarius in the brainstem—enables direct influence over central autonomic and limbic pathways. Notably, VNS may also promote autonomic balance, shifting the nervous system away from chronic stress states. These mechanisms are not only relevant for understanding VNS itself but may inform the design of adjunctive or combination strategies, including the potential pairing of VNS with psychedelic-assisted therapies, an area of growing interest but limited empirical data.

Policy and Research Implications for TRD and Neuromodulation

The strong durability of VNS for TRD, now supported by long-term RECOVER trial outcomes, has significant implications for clinical guidelines and health policy in the United States and beyond. Despite FDA approval, VNS remains underutilized, in part due to reimbursement challenges, surgical risks, and the need for specialized expertise. The new data may prompt reconsideration of payer policies and encourage broader adoption in tertiary care settings. Importantly, the RECOVER trial's rigorous design and extended follow-up offer a concrete benchmark for future neuromodulation trials, including those evaluating non-invasive VNS or other device-based interventions. For researchers and clinicians in the psychedelic field, these findings highlight the value of targeting neuroplasticity and network-level brain changes—mechanisms potentially shared with psychedelic compounds. A non-obvious implication is that VNS's durability in patients with extreme chronicity and refractoriness sets a high bar for any new interventions, including psychedelics, seeking to demonstrate added value in this population.

Risks, Unknowns, and Patient Selection Criteria

Implanted VNS is associated with surgical risks, including infection, vocal cord changes, and device malfunction, though serious adverse events are relatively rare in experienced centers. The durability of benefit does not guarantee universal response: a substantial minority of patients do not achieve meaningful improvement, and predictors of response remain incompletely understood. Current evidence does not clarify whether VNS is best deployed as a monotherapy or in combination with other modalities, nor does it establish optimal sequencing relative to other emerging treatments such as ketamine, esketamine, or psychedelic-assisted therapy. Long-term neurobiological effects, especially in younger or medically complex populations, require further study. The RECOVER trial's rigorous patient selection—severe, unipolar, markedly treatment-resistant depression—means results may not generalize to broader or less refractory populations.

Future Directions: Integrating VNS with Emerging Therapies

VNS's demonstrated durability in TRD provides a foundation for future research into combined and sequential interventions targeting neuroplasticity and brain network dysfunction. Ongoing mechanistic studies may identify biomarkers of response, enabling more personalized treatment approaches. As the field moves toward precision psychiatry, the integration of neuromodulation and pharmacological innovations—including psychedelics—will likely require new trial designs and regulatory frameworks. The RECOVER trial's long-term data serve as a reminder that durable benefit, not just rapid response, is a critical outcome for patients with chronic, refractory depression. Stakeholders should weigh the logistical, ethical, and economic dimensions of expanding access to VNS, especially as adjunctive strategies are developed and tested.

How we research: This article was written and reviewed by Dr. Alex Stein, MD, PhD, on 2026-10-10. Sources include the original RECOVER trial publication, FDA device summaries, and the OpenAlex review (link).